Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

Cancer Immunology, Immunotherapy

Volumn 55, Issue 6, 2006, Pages 717-727

  Adams, Camellia W ^a   Allison, David E ^a   Flagella, Kelly ^a   Presta, Leonard ^a,b   Clarke, Janet ^a,c   Dybdal, Noel ^a   McKeever, Kathleen ^a   Sliwkowski, Mark X ^a  

^a GENENTECH INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BIOGEN   (United States)

Author keywords

2C4; HER dimerization inhibitor (HDI); HER2; Monoclonal antibody humanization; Pertuzumab; rhuMAb 2C4

Indexed keywords

CHIMERIC ANTIBODY; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER DIMERIZATION INHIBITOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; PERTUZUMAB; RECOMBINANT ANTIBODY;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONING VECTOR; COMPARTMENT MODEL; COMPLEMENTARITY DETERMINING REGION; COMPUTER MODEL; CONTROLLED STUDY; DIARRHEA; DIMERIZATION; DNA SEQUENCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; MALE; MOLECULAR CLONING; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RODENT; TOXICITY TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; DIMERIZATION; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MACACA FASCICULARIS; MALE; MICE; PROTEIN STRUCTURE, QUATERNARY; RATS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 33644600485     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0058-x     Document Type: Article

References (55)

1. Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX (2000) A potential role for activated HER-2 in prostate cancer. Semin Oncol 27:76-83
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and tumor growth. Cancer Cell 2:127-137
3. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543
4. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821
5. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552
6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289
7. Chen X, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 277:757-763
8. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760
9. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ (1989) Conformations of immunoglobulin hypervariable regions. Nature 342:877-883
10. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465
11. Dunnett CW (1964) New tables for multiple comparisons with a control. Biometrics 20:482-491
12. Eigenbrot C, Gonzalez T, Mayeda J, Carter P, Werther W, Hotaling T, Fox J, Kessler J (1994) X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65. Proteins 18:49-62
13. Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA (1993) X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 229:969-995
14. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558
15. Fernando NH, Hurwitz HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 30(Suppl 6):39-50
16. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling. Cancer Cell 5:317-328
17. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495-505
18. Gerstner RB, Carter P, Lowman HB (2002) Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol 321:851-862
19. Gorman CM, Gies DR, McCray G (1990) Transient production of proteins using an adenovirus transformed cell line. DNA Prot Eng Tech 2:3-10
20. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74
21. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655
22. Harris KA, Washington CB, Lieberman G, Lu JF, Mass R, Bruno R (2002) A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 21 (abstr 488)
23. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99-110
24. Ings RMJ (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:120-131
25. Jones JT, Akita RW, Sliwkowski MX (1999) Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231
26. Kabat EA, Wu TT, Perry H, Gottesmann KS, Foeller C (1991) Sequences of proteins of immunological interest, 5th edn. Public Health Service, National Institutes of Health Bethesda, MD
27. Keely SJ, Uribe JM, Barrett KE (1998) Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion. J Biol Chem 273:27111-27117
28. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
29. Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82:488-492
30. Lee H, Akita RW, Sliwkowski MX, Maihle NJ (2001) A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 61:4467-4473
31. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971
32. Liu J, Kern JA (2002) Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Resp Cell Mol Biol 27:306-313
33. Malik MA, Totpal K, Balter I, Sliwkowski MX, Pelletier N, Reich M, Crocker L, Friess T, Bauer S, Fiebig HH, Allison DE (2003) Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res 44:150 (abstr 773)
34. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120:1713-1719
35. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62:5485-5488
36. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12
37. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18:5042-5051
38. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
39. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
40. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
41. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623-2632
42. Schroff RW, Foon KAA, Beatty SSM, Odham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885
43. Sias PE, Kotts CE, Vetterlein D, Shepard M, Wong WL (1990) ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132:73-80
44. Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173-183
45. Totpal K, Balter I, Akita R, Bargiacchi F, Phillips GL, Sliwkowski MX (2003) Targeting ErbB2/HER2's role as a coreceptor with rhuMAb2C4 inhibits Erb/HER ligand-dependent signaling and proliferation of ovarian tumor cell lines. Proc Am Assoc Cancer Res 44:151 (abstr 776)
46. Tramontano A, Chothia C, Lesk AM (1990) Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 215:175-182
47. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287
48. Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS (2002) Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol 320:415-428
49. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275
50. Werther WA, Gonzalez TN, O'Conner SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986-4995
51. Winer BJ (1971) Analysis of covariance. In: Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, pp 752-812
52. Winer BJ (1971) Design and analysis of single-factor experiments. In: Statistical principles in experimental design. 2nd edn. McGraw-Hill, New York, pp 149-260
53. Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LT (1995) Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of the heavy-chain hypervariable. J Mol Biol 253:385-390
54. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
55. Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G, Alaoui-Jamali MA (2002) Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 13:4029-4044